Ontology highlight
ABSTRACT:
SUBMITTER: Sumi NJ
PROVIDER: S-EPMC4684772 | biostudies-literature | 2015 Dec
REPOSITORIES: biostudies-literature
Sumi Natalia J NJ Kuenzi Brent M BM Knezevic Claire E CE Remsing Rix Lily L LL Rix Uwe U
ACS chemical biology 20151005 12
Several selective CDK4/6 inhibitors are in clinical trials for non-small cell lung cancer (NSCLC). Palbociclib (PD0332991) is included in the phase II/III Lung-MAP trial for squamous cell lung carcinoma (LUSQ). We noted differential cellular activity between palbociclib and the structurally related ribociclib (LEE011) in LUSQ cells. Applying an unbiased mass spectrometry-based chemoproteomics approach in H157 cells and primary tumor samples, we here report distinct proteome-wide target profiles ...[more]